Alzamend Neuro Missed Consensus Estimates

Alzamend Neuro (ALZN) reported a loss of $0.68 per share on revenue of $0.00 million for the fiscal first quarter ended July 2026. The consensus estimate was a loss of $0.56 per share. The company missed consensus estimates by 21.43%.

Alzamed Neuro is an early clinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Their mission is to rapidly develop and market safe and effective treatments. Their current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.